Live Oak Health Sciences Fund (LOGSX)
20.94
+0.10
(+0.48%)
USD |
Jul 03 2025
Key Stats
Customize
Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
---|---|---|---|
1.03% | 49.06M | 1.02% | 11.00% |
1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
-4.080M | 2.08% | Upgrade | Upgrade |
Basic Info
Investment Strategy | |
The Fund seeks long-term capital growth by investing at least 80% of its net assets in common stocks of companies engaged in the research, development, production or distribution of products or services related to health care, medicine, or the life sciences. The Fund is non-diversified and will only hold a few stocks. |
General | |
Security Type | Mutual Fund |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Global Peer Group | Equity Sector Healthcare |
Peer Group | Health/Biotechnology Funds |
Global Macro | Equity Industry Sector |
US Macro | Sector Equity Funds |
YCharts Categorization | -- |
YCharts Benchmark | -- |
Prospectus Objective | Health/Biotechnology Funds |
Fund Owner Firm Name | Oak Associates |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
6
-855.68M
Peer Group Low
19.37M
Peer Group High
1 Year
% Rank:
22
-4.080M
-2.481B
Peer Group Low
10.00M
Peer Group High
3 Months
% Rank:
21
-1.293B
Peer Group Low
15.94M
Peer Group High
3 Years
% Rank:
24
-6.960B
Peer Group Low
87.29M
Peer Group High
6 Months
% Rank:
23
-1.663B
Peer Group Low
10.00M
Peer Group High
5 Years
% Rank:
30
-6.729B
Peer Group Low
4.689B
Peer Group High
YTD
% Rank:
23
-1.663B
Peer Group Low
10.00M
Peer Group High
10 Years
% Rank:
34
-12.22B
Peer Group Low
5.565B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of July 07, 2025.
Asset Allocation
As of March 31, 2025.
Type | % Net |
---|---|
Cash | 3.93% |
Stock | 96.07% |
Bond | 0.00% |
Convertible | 0.00% |
Preferred | 0.00% |
Other | 0.00% |
Top 10 Holdings
Name | % Weight | Price | % Change |
---|---|---|---|
McKesson Corp | 6.26% | 719.30 | 1.96% |
Cencora Inc | 5.73% | 296.23 | 1.74% |
Amgen Inc | 5.52% | 298.24 | 0.47% |
Cardinal Health Inc | 4.39% | 164.93 | 1.82% |
Exelixis Inc | 4.35% | 46.15 | 4.18% |
The Cigna Group | 4.07% | 319.75 | -0.20% |
Regeneron Pharmaceuticals Inc | 4.04% | 547.36 | -0.07% |
JPMorgan Chase & Co Repo
|
3.93% | -- | -- |
Novartis AG | 3.82% | 121.90 | -1.54% |
Vertex Pharmaceuticals Inc | 3.80% | 459.62 | 0.57% |
Fees & Availability
Fees | |
Actual 12B-1 Fee | -- |
Actual Management Fee | 0.74% |
Administration Fee | 27.40K% |
Maximum Front Load | -- |
Maximum Deferred Load | -- |
Maximum Redemption Fee | -- |
General Availability | |
Available for Insurance Product | -- |
Available for RRSP | -- |
Purchase Details | |
Open to New Investors |
|
Minimum Initial Investment | 2000.00 None |
Minimum Subsequent Investment | 25.00 None |
Basic Info
Investment Strategy | |
The Fund seeks long-term capital growth by investing at least 80% of its net assets in common stocks of companies engaged in the research, development, production or distribution of products or services related to health care, medicine, or the life sciences. The Fund is non-diversified and will only hold a few stocks. |
General | |
Security Type | Mutual Fund |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Global Peer Group | Equity Sector Healthcare |
Peer Group | Health/Biotechnology Funds |
Global Macro | Equity Industry Sector |
US Macro | Sector Equity Funds |
YCharts Categorization | -- |
YCharts Benchmark | -- |
Prospectus Objective | Health/Biotechnology Funds |
Fund Owner Firm Name | Oak Associates |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Fundamentals
General | |
Distribution Yield | -- |
Dividend Yield TTM (7-2-25) | 0.69% |
30-Day SEC Yield | -- |
7-Day SEC Yield | -- |
Stock | |
Weighted Average PE Ratio | 30.79 |
Weighted Average Price to Sales Ratio | 3.887 |
Weighted Average Price to Book Ratio | 7.600 |
Weighted Median ROE | 33.96% |
Weighted Median ROA | 6.57% |
ROI (TTM) | 10.98% |
Return on Investment (TTM) | 10.98% |
Earning Yield | 0.0407 |
LT Debt / Shareholders Equity | 2.270 |
As of March 31, 2025
Growth Metrics
EPS Growth (1Y) | 18.54% |
EPS Growth (3Y) | 5.44% |
EPS Growth (5Y) | 6.39% |
Sales Growth (1Y) | 11.64% |
Sales Growth (3Y) | 9.19% |
Sales Growth (5Y) | 10.79% |
Sales per Share Growth (1Y) | 14.45% |
Sales per Share Growth (3Y) | 11.20% |
Operating Cash Flow - Growth Ratge (3Y) | 3.44% |
As of March 31, 2025
Fund Details
Key Dates | |
Inception Date | 6/29/2001 |
Last Annual Report Date | 10/31/2024 |
Last Prospectus Date | 2/28/2025 |
Attributes | |
Index Fund | -- |
Inverse Fund | -- |
Leveraged Fund | -- |
Fund of Funds | No |
Currency Hedged Fund | -- |
Synthetic Replication Fund | No |
Top Portfolio Holders
Name | % Weight |
---|---|
Portfolio A | 5.00% |
Portfolio B | 3.50% |
Portfolio C | 2.25% |
Excel Add-In Codes
Name: =YCI("M:LOGSX", "name") |
Broad Asset Class: =YCI("M:LOGSX", "broad_asset_class") |
Broad Category: =YCI("M:LOGSX", "broad_category_group") |
Prospectus Objective: =YCI("M:LOGSX", "prospectus_objective") |
To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |